{"id":"NCT03321968","sponsor":"Medicago","briefTitle":"Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults","officialTitle":"A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Healthy Adults 18-49 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-29","primaryCompletion":"2017-12-01","completion":"2017-12-01","firstPosted":"2017-10-26","resultsPosted":"2023-08-04","lastUpdate":"2023-08-04"},"enrollment":1202,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"OTHER"},"conditions":["Virus Diseases","RNA Virus Infections","Respiratory Tract Infections","Respiratory Tract Disease","Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent VLP Influenza Vaccine","otherNames":[]}],"arms":[{"label":"Quadrivalent VLP Influenza Vaccine - Lot 1","type":"EXPERIMENTAL"},{"label":"Quadrivalent VLP Influenza Vaccine - Lot 2","type":"EXPERIMENTAL"},{"label":"Quadrivalent VLP Influenza Vaccine - Lot 3","type":"EXPERIMENTAL"}],"summary":"This Phase 3 study is intended to assess the clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three consecutively manufactured lots of the Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine, during the 2016-2017 influenza season, in healthy adults 18-49 years of age. A single dose of one of three consecutive lots of Quadrivalent VLP Influenza Vaccine (30 Âµg/strain) will be administered to 1,200 participants.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain","timeFrame":"Day 21 (post-vaccination)","effectByArm":[{"arm":"Quadrivalent VLP Influenza Vaccine - Lot 1","deltaMin":603.7,"sd":null},{"arm":"Quadrivalent VLP Influenza Vaccine - Lot 2","deltaMin":595.6,"sd":null},{"arm":"Quadrivalent VLP Influenza Vaccine - Lot 3","deltaMin":630.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["Canada"]},"refs":{"pmids":["33581920"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":401},"commonTop":["Viral upper respiratory tract infection","Headache","Oropharyngeal pain","Nasal congestion","Nausea"]}}